Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Center, Randomized, Placebo-Controlled Trial to Establish Maximum Tolerated Dose, Optimal Titration Schedule, Safety, Tolerability, and Pharmacokinetics of Org 26576 in Patients Diagnosed With Major Depressive Disorder (Protocol No. P174001)
Brief Summary: Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.


Options:
A: Arm Label: Esketamine low dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - low dose | Arm Label: Esketamine medium dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - medium dose | Arm Label: Esketamine high dose; Type: EXPERIMENTAL; Interventions: Drug: Esketamine DPI - high dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo DPI | Intervention Type: DRUG; Name: Esketamine DPI - low dose; Assigned to Arm(s): Esketamine low dose | Intervention Type: DRUG; Name: Esketamine DPI - medium dose; Assigned to Arm(s): Esketamine medium dose | Intervention Type: DRUG; Name: Esketamine DPI - high dose; Assigned to Arm(s): Esketamine high dose | Intervention Type: DRUG; Name: Placebo DPI; Assigned to Arm(s): Placebo
B: Arm Label: Part 1: Block A MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block B MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block B Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block C MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block C Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 1: Block D MK-8777; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 1: Block D Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: MK-8777 200 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 2: MK-8777 800 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-8777 | Arm Label: Part 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: MK-8777; Assigned to Arm(s): Part 1: Block A MK-8777, Part 1: Block B MK-8777, Part 1: Block C MK-8777, Part 1: Block D MK-8777, Part 2: MK-8777 200 mg, Part 2: MK-8777 800 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Block A Placebo, Part 1: Block B Placebo, Part 1: Block C Placebo, Part 1: Block D Placebo, Part 2: Placebo
C: Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: N-acetyl-cysteine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: N-acetyl-cysteine (NAC) | Arm Label: Aspirin and NAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Dietary Supplement: N-acetyl-cysteine (NAC) | Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sugar Pill | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin, Aspirin and NAC | Intervention Type: DIETARY_SUPPLEMENT; Name: N-acetyl-cysteine (NAC); Assigned to Arm(s): Aspirin and NAC, N-acetyl-cysteine | Intervention Type: DRUG; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill
D: Arm Label: sarcosine; Type: EXPERIMENTAL; Interventions: Drug: sarcosine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: sarcosine; Assigned to Arm(s): sarcosine

Answer: B